Biomarkers最新文献

筛选
英文 中文
The Prognostic Value of the Inflammation-Immunity-Nutrition Score in Advanced Non-Small Cell Lung Cancer Undergoing First-Line Immunotherapy: A 3-Year Retrospective Cohort Study. 炎症-免疫-营养评分对接受一线免疫治疗的晚期非小细胞肺癌的预后价值:一项为期3年的回顾性队列研究
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-16 DOI: 10.1080/1354750X.2026.2765438
Wen-Jian Liu, Kai Cui, Jian-Hui Zuo
{"title":"The Prognostic Value of the Inflammation-Immunity-Nutrition Score in Advanced Non-Small Cell Lung Cancer Undergoing First-Line Immunotherapy: A 3-Year Retrospective Cohort Study.","authors":"Wen-Jian Liu, Kai Cui, Jian-Hui Zuo","doi":"10.1080/1354750X.2026.2765438","DOIUrl":"https://doi.org/10.1080/1354750X.2026.2765438","url":null,"abstract":"<p><strong>Objective: </strong>This study preliminarily evaluated the prognostic value of the inflammation-immunity-nutrition score (IINS) in advanced NSCLC patients receiving first-line immunotherapy.</p><p><strong>Methods: </strong>This retrospective, single-center study enrolled 212 patients. Patients were categorized into the death group, survival group, progressive disease (PD) group, and non-PD (N-PD) group. Prognosis analysis employed Cox regression, Kaplan-Meier (KM) survival curves, and ROC curves. Internal validation was performed using the Bootstrap method and a 10-fold cross-validation approach, and calibration curves were plotted.</p><p><strong>Results: </strong>High IINS was associated with poorly differentiated tumors, stage IV disease, and ≥2 metastases. Patients with PD or death had significantly higher IINS. After adjusting for available confounding factors, a higher IINS remained associated with PD and death. IINS may aid in the prognostic assessments of PD and death within 3 years, with good model performance in internal validation. High-risk patients showed reduced survival.</p><p><strong>Conclusion: </strong>Higher IINS correlates with poor 3-year prognosis. Given the limitations of the retrospective, single-center design, the absence of a non-immunotherapy control group, and the failure to adjust for certain key confounding factors, the above conclusions should be regarded as preliminary, hypothesis-generating findings that require external validation through prospective, multicenter studies.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-18"},"PeriodicalIF":2.2,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149416938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbiota-derived extracellular vesicles in cancer prognosis: a systematic review and contextual evidence map of EV-associated microbial signals. 微生物来源的细胞外囊泡与癌症预后:ev相关微生物信号的系统回顾和背景证据图。
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-06 DOI: 10.1080/1354750X.2026.2754024
Servet Doğaç Topçu, Mahmut Çerkez Ergören
{"title":"Microbiota-derived extracellular vesicles in cancer prognosis: a systematic review and contextual evidence map of EV-associated microbial signals.","authors":"Servet Doğaç Topçu, Mahmut Çerkez Ergören","doi":"10.1080/1354750X.2026.2754024","DOIUrl":"10.1080/1354750X.2026.2754024","url":null,"abstract":"<p><strong>Background: </strong>Microbiota-derived extracellular vesicles (EVs) are proposed as oncology biomarkers, but microbial vesicles and microbial signals in heterogeneous or host-EV preparations are not biologically equivalent.</p><p><strong>Methods: </strong>We revised a prospectively registered systematic review of human cancer studies relating microbiota-derived EVs measured at or before prognostic baseline to time-to-event outcomes. Peer-review reruns covered PubMed, Scopus, Web of Science Core Collection, CENTRAL, and Embase. Biological provenance was re-adjudicated; QUIPS, REMARK-informed items, PROBAST where applicable, and GRADE-Prognosis informed appraisal.</p><p><strong>Results: </strong>The update identified 9,862 records; 5,837 unique records remained after 4,025 duplicates were removed. Two P1 studies reported time-to-event associations. Fujikawa 2025, the only fully protocol-concordant study, found lower 5-year RFS with high versus low serum-EV BAF (66.5% vs 91.3%; <i>p</i> = 0.042). Uemura 2023 found shorter PFS (8 vs 20 months; <i>p</i> = 0.04) and OS (19 months vs not reached; <i>p</i> = 0.03) with high serum-EV Bacteroidia, but prognostic-baseline sampling time was unreported. Four P3 studies provided contextual outcome/treatment-response evidence. No study established treatment-specific predictive utility.</p><p><strong>Conclusions: </strong>Evidence remains sparse and heterogeneous. Microbial-vesicle identity, baseline timing, independent prognostic value, and external validation must be demonstrated together before clinical use.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Next Steps for Cardiovascular Biomarkers: From Measurement to Clinical Decisions. 心血管生物标志物的下一步:从测量到临床决策。
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-04 DOI: 10.1080/1354750X.2026.2759682
Lori B Daniels
{"title":"Next Steps for Cardiovascular Biomarkers: From Measurement to Clinical Decisions.","authors":"Lori B Daniels","doi":"10.1080/1354750X.2026.2759682","DOIUrl":"10.1080/1354750X.2026.2759682","url":null,"abstract":"<p><p>Cardiovascular biomarkers have transformed diagnosis and risk assessment, but outside of acute care their results rarely change treatment. This editorial argues that the next phase of biomarker research should focus on linking results to defined clinical actions. Guidelines now support natriuretic peptide and high-sensitivity cardiac troponin testing to identify pre-heart failure in adults with diabetes and other high-risk groups. However, trials are still needed to establish what a positive result should trigger, including whether specific drug classes, such as renin-angiotensin system inhibitors, offer greater benefit in biomarker-positive patients. Recent negative trials of therapies aimed at lowering lipoprotein(a) and interleukin-6 underscore the difference between using biomarkers to select patients and treating them as therapeutic targets. Dipeptidyl peptidase 3, developed in parallel with a neutralizing antibody being evaluated for treatment of shock, illustrates a model in which assay and therapy advance together. Progress will depend on validated thresholds, drug class trials, companion diagnostics, and reimbursement.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-6"},"PeriodicalIF":2.2,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lessons learned from predicting hospital admission criteria comparing two COVID-19 waves: an emergency department's perspective. 从预测住院标准比较两次COVID-19浪潮的经验教训:急诊科的角度。
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-03 DOI: 10.1080/1354750X.2026.2725728
Miriam Mayer, Anna Slagman, Samipa Pudasaini, Kira Louisa Boldt, Mareen Pigorsch, Jennifer Hitzek, Martin Möckel
{"title":"Lessons learned from predicting hospital admission criteria comparing two COVID-19 waves: an emergency department's perspective.","authors":"Miriam Mayer, Anna Slagman, Samipa Pudasaini, Kira Louisa Boldt, Mareen Pigorsch, Jennifer Hitzek, Martin Möckel","doi":"10.1080/1354750X.2026.2725728","DOIUrl":"10.1080/1354750X.2026.2725728","url":null,"abstract":"<p><strong>Methods: </strong>This study compares patient characteristics, clinical biomarkers and outcomes during wave 1 (W1) and wave 2 (W2) of the COVID-19 pandemic at two tertiary care EDs in Berlin. We validated parameters predicting hospital admission by a CART-analysis of W1 in W2 and compared the findings to a CART-model derived from W2 by a decision curve analysis.</p><p><strong>Results: </strong>A total of 1204 patients with suspected COVID-19 presented in W1 and 1,440 in W2; 106 in W1 and 722 in W2 tested positive. Patients in W2 were older (>65 years, W1: 22.2%; W2: 34.6%) and multimorbid. Mortality of positive tested (W1: 1.9%; W2:8.6%) rose in W2. The admission-predicting parameters O2 saturation <95%, dyspnea, and cardiovascular comorbidities of W1 were applicable with a sensitivity of 98.5% (CI-95%: 96.3 - 99.4%) and specificity of 68.4% (61.0-74.9%) in W2.</p><p><strong>Conclusions: </strong>Our results show transferability of admission-criteria despite changing pandemic conditions and serve as lessons learned to support future pandemic preparedness and capacity planning.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148981913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic value of serum neuron-specific enolase and S100 calcium-binding protein B for sepsis-associated encephalopathy: a systematic review and meta-analysis. 血清神经元特异性烯醇化酶和S100钙结合蛋白B对败血症相关脑病的诊断价值:系统回顾和荟萃分析
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-01 Epub Date: 2026-08-27 DOI: 10.1080/1354750X.2026.2722073
Zhang Li, Shuyu Zhong, Minjing Chen, Huan Chen
{"title":"Diagnostic value of serum neuron-specific enolase and S100 calcium-binding protein B for sepsis-associated encephalopathy: a systematic review and meta-analysis.","authors":"Zhang Li, Shuyu Zhong, Minjing Chen, Huan Chen","doi":"10.1080/1354750X.2026.2722073","DOIUrl":"10.1080/1354750X.2026.2722073","url":null,"abstract":"<p><strong>Background: </strong>Sepsis-associated encephalopathy (SAE) is a frequent and serious complication of sepsis, but reliable diagnostic biomarkers remain limited.</p><p><strong>Objective: </strong>To evaluate the diagnostic value of serum neuron-specific enolase (NSE) and S100 calcium-binding protein B (S100B) in distinguishing SAE from sepsis without SAE.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Embase and Web of Science between inception and January 2026. Studies comparing serum NSE and/or S100B levels between patients with SAE and patients with sepsis without SAE were included.</p><p><strong>Results: </strong>Eight studies involving 722 participants (323 with SAE and 399 with sepsis but no SAE) were included. Both NSE and S100B levels were significantly elevated in the SAE group compared with the sepsis without SAE group. The pooled standardized mean difference (SMD) for NSE was 0.82 (95% confidence interval [CI]: 0.66-0.97, P < 0.001, I<sup>2</sup> = 0.0%), indicating a large effect size with minimal heterogeneity. The pooled SMD for S100B was 0.94 (95% CI: 0.77-1.11, P < 0.001, I<sup>2</sup> = 0.0%), also demonstrating a large effect size.</p><p><strong>Conclusions: </strong>Serum NSE and S100B are significantly elevated in SAE and may help identify SAE early in patients with sepsis.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"485-493"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined metabolic-inflammatory biomarkers for predicting complicated acute appendicitis: a comparative analysis. 联合代谢-炎症生物标志物预测复杂急性阑尾炎:比较分析。
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-01 Epub Date: 2026-09-02 DOI: 10.1080/1354750X.2026.2725727
Nur Kezban Akman, Hikmet Pehlevan Özel, Derviş Duru, Yusuf Yilmaz, Sedat Kıran, Tezcan Akın, Sadettin Er, Özgür Akgül, Mesut Tez
{"title":"Combined metabolic-inflammatory biomarkers for predicting complicated acute appendicitis: a comparative analysis.","authors":"Nur Kezban Akman, Hikmet Pehlevan Özel, Derviş Duru, Yusuf Yilmaz, Sedat Kıran, Tezcan Akın, Sadettin Er, Özgür Akgül, Mesut Tez","doi":"10.1080/1354750X.2026.2725727","DOIUrl":"10.1080/1354750X.2026.2725727","url":null,"abstract":"<p><strong>Introduction: </strong>Early identification of complicated acute appendicitis remains clinically important for guiding timely surgical management. Composite indices integrating metabolic and inflammatory parameters have recently been proposed as potential predictors of disease severity. This study aimed to compare the diagnostic performance of metabolic-inflammatory composite indices with conventional hematological markers in predicting complicated acute appendicitis.</p><p><strong>Methods: </strong>This retrospective cohort study included adult patients who underwent appendectomy between January 2022 and January 2025. Complicated appendicitis was defined by intraoperative findings of perforation, gangrene, periappendiceal abscess, or generalized peritonitis. Various inflammatory and metabolic indices were calculated from routine laboratory parameters. Diagnostic performance was evaluated using ROC analysis and logistic regression models.</p><p><strong>Results: </strong>A total of 1,871 patients were included, of whom 210 (11.2%) had complicated appendicitis. The C-reactive protein-to-albumin ratio (CAR) showed the highest diagnostic performance (AUC = 0.734). In multivariable analysis, both CAR and the inflammatory metabolic index (IMI) remained independent predictors. The final model incorporating age, sex, CAR, and IMI demonstrated the best discriminative performance (AUC = 0.795).</p><p><strong>Conclusion: </strong>Metabolic-inflammatory composite biomarkers, particularly CAR, may provide valuable adjunctive information for early prediction of complicated acute appendicitis.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"511-519"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of colchicine on C-reactive protein level following hospitalization for myocardial infarction: a meta-analysis of randomized, placebo-controlled trials. 秋水仙碱对心肌梗死住院后c反应蛋白水平的影响:随机、安慰剂对照试验的荟萃分析
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-01 Epub Date: 2026-09-07 DOI: 10.1080/1354750X.2026.2726961
Srikiran Dasari, Thomas Fretz, John Sakaleros, Eduardo Aviles, Rishith Mishra, Celestine Willie, David Santistevan, Mohammad Thawabi
{"title":"Effect of colchicine on C-reactive protein level following hospitalization for myocardial infarction: a meta-analysis of randomized, placebo-controlled trials.","authors":"Srikiran Dasari, Thomas Fretz, John Sakaleros, Eduardo Aviles, Rishith Mishra, Celestine Willie, David Santistevan, Mohammad Thawabi","doi":"10.1080/1354750X.2026.2726961","DOIUrl":"10.1080/1354750X.2026.2726961","url":null,"abstract":"<p><strong>Background: </strong>C-reactive protein (CRP) is a biomarker of vascular inflammation with prognostic value for future cardiovascular events. This meta-analysis investigates the effect of colchicine, a cheap and widely available anti-inflammatory medication, on CRP levels in the months following myocardial infarction (MI).</p><p><strong>Methods: </strong>PubMed, EMBASE, and Cochrane were queried from inception to April 2026 to identify randomized controlled trials comparing colchicine to placebo for at least 1 month following MI. The primary outcome was mean CRP level at follow-up. Effect estimates were pooled with random-effects models and reported as mean differences for continuous variables using 95% confidence intervals.</p><p><strong>Results: </strong>Four studies met inclusion criteria comprising 3384 patients (mean age 60.7 years; 78.3% male), including 1669 patients randomized to the colchicine arm, and 1715 to placebo. Median follow-up period was 3 months (range: 1-6 months). Colchicine following MI resulted in a statistically significant decrease in mean CRP level (mg/L) at follow-up versus placebo (MD: -0.69; [-1.21, -0.17], <i>p</i> = 0.009). Heterogeneity of effect size estimates was high (I<sup>2</sup> = 97%).</p><p><strong>Conclusion: </strong>Daily colchicine following MI decreases CRP at a median follow-up period of 3 months compared to placebo. The correlation between CRP reduction with colchicine and adverse cardiovascular event reduction warrants additional study.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"520-528"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148856916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-dependent changes in YKL-40 and inflammatory markers in experimental acute mesenteric ischaemia. 实验性急性肠系膜缺血中YKL-40和炎症标志物的时间依赖性变化。
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-01 Epub Date: 2026-09-10 DOI: 10.1080/1354750X.2026.2723432
Muhammed Ali Akbulut, Mehmet Aykut Yıldırım, Rahim Kocabaş, Fahriye Kılınç, Abdullah Gürhan Duyan
{"title":"Time-dependent changes in YKL-40 and inflammatory markers in experimental acute mesenteric ischaemia.","authors":"Muhammed Ali Akbulut, Mehmet Aykut Yıldırım, Rahim Kocabaş, Fahriye Kılınç, Abdullah Gürhan Duyan","doi":"10.1080/1354750X.2026.2723432","DOIUrl":"10.1080/1354750X.2026.2723432","url":null,"abstract":"<p><strong>Background: </strong>Early diagnosis of acute mesenteric ischaemia (AMI) remains challenging due to the lack of reliable biomarkers. This study aimed to investigate the time-dependent changes in chitinase-3-like protein 1 (YKL-40) and selected inflammatory markers in an experimental AMI model.</p><p><strong>Methods: </strong>A randomized controlled experimental study was conducted on 48 Wistar-albino rats. Mesenteric ischaemia was induced by ligation of the superior mesenteric artery. Blood and tissue samples were collected at 1, 3 and 6 h. Serum YKL-40, interleukin-6 (IL-6), interleukin-10 (IL-10) and lactate levels were measured, and histopathological damage was assessed.</p><p><strong>Results: </strong>IL-6 levels increased significantly as early as 1 h (<i>p</i> = 0.010) and showed a progressive rise over time (<i>p</i> < 0.001), with a strong positive correlation with histopathological damage (<i>r</i> = 0.805). Lactate levels increased significantly at later time points. YKL-40 levels did not differ in the early phase but were significantly elevated at 6 h (<i>p</i> < 0.001). IL-10 levels decreased significantly in advanced ischaemia (<i>p</i> = 0.005).</p><p><strong>Conclusion: </strong>IL-6 showed an early increase and a strong association with histopathological damage, whereas YKL-40 appeared to be associated with later-stage inflammation rather than early ischaemic injury. These findings highlight the importance of time-dependent biomarker interpretation and support further evaluation of combined biomarker strategies in AMI.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"494-501"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between the Geriatric Nutritional Risk Index and the risk of readmission in older inpatients: a systematic review and meta-analysis. 老年营养风险指数与老年住院患者再入院风险之间的关系:系统回顾和荟萃分析。
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-11-01 Epub Date: 2026-09-03 DOI: 10.1080/1354750X.2026.2725723
Jing Wang, Guifang Liao, Qiwu Jin
{"title":"Association between the Geriatric Nutritional Risk Index and the risk of readmission in older inpatients: a systematic review and meta-analysis.","authors":"Jing Wang, Guifang Liao, Qiwu Jin","doi":"10.1080/1354750X.2026.2725723","DOIUrl":"10.1080/1354750X.2026.2725723","url":null,"abstract":"<p><strong>Background: </strong>The Geriatric Nutritional Risk Index (GNRI) is associated with readmission risk in older inpatients, but evidence is from single-centre studies.</p><p><strong>Aim: </strong>To quantify the association between GNRI and readmission risk, total hospital stay and intensive care unit (ICU) stay in older hospitalized patients.</p><p><strong>Methods: </strong>Searched Cochrane Library, Web of Science, PubMed and Embase until 23 October 2024 for case-control or cohort studies on GNRI and readmission in patients aged ≥60. Study quality was assessed using the Newcastle-Ottawa Scale. Analyses were performed in Stata 15.0 using random- or fixed-effects models based on heterogeneity (<i>I</i><sup>2</sup>≥50%, <i>p</i> < 0.05). Effect sizes were reported as relative risk (RR) or standardized mean difference (SMD) with 95% confidence intervals (CI). Subgroup and sensitivity analyses were conducted.</p><p><strong>Results: </strong>Thirty-six studies were included. Twelve studies (<i>n</i> = 234,116) confirmed lower readmission risk in the high-GNRI group (RR = 0.60, 95%CI: 0.53-0.68; <i>I</i><sup>2</sup> = 70.8%). Twenty-six studies (<i>n</i> = 30,461) showed shorter total hospital and ICU stays.</p><p><strong>Conclusions: </strong>Lower GNRI is significantly associated with higher readmission risk and longer total hospital and ICU stays in older inpatients, supporting its role as a biomarker for adverse outcomes.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"502-510"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miR-570 in cancer: context-dependent molecular functions, regulatory networks, biomarker potential, and therapeutic perspectives. miR-570在癌症中的作用:环境依赖的分子功能、调控网络、生物标志物潜力和治疗前景。
IF 2.2 4区 医学
Biomarkers Pub Date : 2026-10-29 DOI: 10.1080/1354750X.2026.2754025
Juan Liu, Pingping Bing, Xi Li
{"title":"miR-570 in cancer: context-dependent molecular functions, regulatory networks, biomarker potential, and therapeutic perspectives.","authors":"Juan Liu, Pingping Bing, Xi Li","doi":"10.1080/1354750X.2026.2754025","DOIUrl":"10.1080/1354750X.2026.2754025","url":null,"abstract":"<p><p>MicroRNA-570 (miR-570), particularly miR-570-3p, has emerged as a context-dependent regulator of cancer biology with both tumor-suppressive and oncogenic functions. This review summarizes current evidence on the molecular regulation, functional roles, genetic variation, biomarker potential, and therapeutic targeting of the miR-570 network. miR-570 expression is controlled by epigenetic remodeling, DNA methylation, genomic copy-number variation, competing endogenous RNAs, and extracellular-vesicle transport. In tumor-suppressive settings, miR-570 restrains proliferation, metabolism, proteostasis, invasion, immune-checkpoint expression, stemness, treatment resistance, and metastasis through targets including DPP4, PD-L1, SPP1, IRS1/2, LCMR1, ATG12, and chaperome components. Conversely, it may promote malignancy by repressing MX2, FOXO3, PTEN, KLF9, and KLF10. These opposing effects are shaped by tumor lineage, mature strand, cellular source, target abundance, ceRNA buffering, genetic variants, and treatment state. Clinical studies suggest context-dependent diagnostic and prognostic relevance, while evidence for predictive or pharmacodynamic applications remains insufficient due to methodological heterogeneity, limited external validation, and inconsistent strand-specific measurement. Therapeutic restoration, inhibition, ceRNA targeting, and epigenetic reactivation remain promising but require molecular patient selection and precise cell-specific delivery. Future translation depends on standardized assays, direct target validation, cell-resolved profiling, and rigorous preclinical safety assessment. Accordingly, miR-570 should be viewed as a context-defined network rather than an isolated biomarker.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-24"},"PeriodicalIF":2.2,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书